BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15080063)

  • 1. [Combined treatment for pain from bone metastases in patients with prostate cancer].
    Ren X; Ying J; Yao D; Ye C; Jiang Y
    Zhonghua Nan Ke Xue; 2004 Mar; 10(3):188-90. PubMed ID: 15080063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter study to determine the efficacy and safety of strontium (89Sr) chloride for palliation of painful bony metastases in cancer patients].
    Nishio M; Sano M; Tamaki Y; Fujii H; Shima Y; Fujimoto H; Kubo A; Koizumi K; Tokuda Y; Adachi S; Sumiyoshi Y; Hasegawa T; Eguchi K
    Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Oct; 65(4):399-410. PubMed ID: 16334394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
    Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
    J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D; Spaas P; Specenier P
    Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Internal strontium-89 radiotherapy for malignant bony metastasis].
    Lou C; Zhang D; Yu L
    Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):507-9. PubMed ID: 11859724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT; McEwan AJ
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
    Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.